Stocks were set to open little changed on Thursday as investors grappled with euro zone uncertainty, a raft of corporate earnings and softer-than-expected data on the domestic labor market.
Carl Icahn sued Amylin Pharmaceuticals Inc to block enforcement of a bylaw that prevents the billionaire investor from launching a proxy fight that could lead to a sale of the maker of diabetes drugs.
Carl Icahn sued Amylin Pharmaceuticals Inc to block enforcement of a bylaw that prevents the billionaire investor from launching a proxy fight that could lead to a sale of the maker of diabetes drugs.
Power producer Dynegy Inc. announced Thursday it settled disputes with creditors, putting one of its subsidiaries closer to emerging from bankruptcy protection.
Hedge fund manager Philip Falcone said in an interview on Wednesday he is seriously considering filing a voluntary bankruptcy for LightSquared, the struggling telecom startup in which his Harbinger Capital Partners is the majority owner.
The primary advocate group for former MF Global customers is undertaking an effort to convert the commodities broker's bankruptcy status to one that allows a more streamlined liquidation process, saying it would preserve more potential payback for customers.
Auto parts supplier Federal-Mogul Corp said on Monday Chief Executive Jose Maria Alapont will retire at the end of this month and the maker of powertrain and safety technology will create an independent aftermarket division.
Hedge fund manager Philip Falcone started 2012 with a series of setbacks, but there is one thing he can still count on this year: membership in the hyper-exclusive club of the world's richest people.
Motorola Solutions (NYSE: MSI) announced on Monday it will buy back $1.17 billion in stock from billionaire activist investor Carl Icahn.
Activist investor Carl Icahn announced Thursday he was sweetening a takeover offer for independent petroleum refiner CVR Energy Inc. (NYSE:CVI), proposing to buy all outstanding shares of the company, in cash, at $30 a share.
New Yahoo CEO Scott Thomson faces a new nightmare: activist shareholder Third Point Capital has upped its holdings and launched a proxy battle to control the company.
Even in defeat, Carl Icahn can change companies.
Oshkosh Corp. shareholders handed a defeat to activist investor Carl Icahn on Friday, electing at least 12 of the 13 management-backed nominees to the company's board.
Hedge fund manager Philip Falcone is looking at the possibility of selling some wireless assets to raise cash for his financially strapped telecom start-up LightSquared Inc, sources familiar with the matter said on Friday.
Billionaire investor Carl Icahn is buying some of the debt of hedge fund manager Philip Falcone's LightSquared Inc as the ailing wireless-network company runs short of cash, according to two sources familiar with the matter.
Billionaire investor Carl Icahn is buying some of the debt of hedge fund manager Philip Falcone's LightSquared Inc. as the ailing wireless-network company runs short of cash, according to two sources familiar with the matter.
The top aftermarket NYSE gainers on Friday were: AOL, CVR Energy, Frontline, Dolby Laboratories and Covance. The top after market NYSE Losers were: Wabash National Corp, Kemet Corp, Walter Energy, Primerica and Teekay Tankers.
Lions Gate Entertainment Corp said it bought private movie studio Summit Entertainment, producer of the blockbuster Twilight vampire series, for $412.5 million in cash and stock.
Shares in Research In Motion climbed nearly 4 percent on Thursday on market speculation the BlackBerry maker had hired investment bank Goldman Sachs to explore strategic options.
Billionaire investor Carl Icahn on Wednesday dropped his $1.73 billion hostile bid for Commercial Metals Co (CMC.N) after failing to pick up support among the metal company's other shareholders.
Billionaire investor Carl Icahn on Wednesday dropped his $1.73 billion hostile bid for Commercial Metals Co after failing to pick up support among the metal company's other shareholders.
WebMD Health Corp said it called off discussions with potential acquirers and warned that 2012 profit would be significantly lower as clients slash expenses to offset revenue loss from drugs losing patent protection.
